|
1
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al TRACERx Consortium, : Tracking the evolution of
non-small-cell lung cancer. N Engl J Med. 376:2109–2121. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu L, Zhou XY, Zhang JQ, Wang GG, He J,
Chen YY, Huang C, Li L and Li SQ: LncRNA HULC promotes non-small
cell lung cancer cell proliferation and inhibits the apoptosis by
up-regulating sphingosine kinase 1 (SPHK1) and its downstream
PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 22:8722–8730.
2018.PubMed/NCBI
|
|
3
|
Peters S, Camidge DR, Shaw AT, Gadgeel S,
Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al
ALEX Trial Investigators, : Alectinib versus crizotinib in
untreated ALK-positive non-small-cell lung cancer. N Engl J Med.
377:829–838. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rotow J and Bivona TG: Understanding and
targeting resistance mechanisms in NSCLC. Nat Rev Cancer.
17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hendriks LEL and Dingemans AC: Heat shock
protein antagonists in early stage clinical trials for NSCLC.
Expert Opin Investig Drugs. 26:541–550. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma K, Fan Y, Dong X, Dong D, Guo Y, Wei X,
Ning J, Geng Q, Wang C, Hu Y, et al: MTA1 promotes epithelial to
mesenchymal transition and metastasis in non-small-cell lung
cancer. Oncotarget. 8:38825–38840. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu X, Guo Y, Li X, Ding Y and Chen L:
Metastasis-associated protein 1 nuclear expression is associated
with tumor progression and clinical outcome in patients with
non-small cell lung cancer. J Thorac Oncol. 5:1159–1166. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hofer MD, Tapia C, Browne TJ, Mirlacher M,
Sauter G and Rubin MA: Comprehensive analysis of the expression of
the metastasis-associated gene 1 in human neoplastic tissue. Arch
Pathol Lab Med. 130:989–996. 2006.PubMed/NCBI
|
|
9
|
Sasaki H, Moriyama S, Nakashima Y,
Kobayashi Y, Yukiue H, Kaji M, Fukai I, Kiriyama M, Yamakawa Y and
Fujii Y: Expression of the MTA1 mRNA in advanced lung cancer. Lung
Cancer. 35:149–154. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swensen SJ: CT screening for lung cancer.
AJR Am J Roentgenol. 179:833–836. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goss G, Tsai CM, Shepherd FA, Ahn MJ,
Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R,
et al: CNS response to osimertinib in patients with T790M-positive
advanced NSCLC: Pooled data from two phase II trials. Ann Oncol.
29:687–693. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jagadish N, Parashar D, Gupta N, Agarwal
S, Sharma A, Fatima R, Suri V, Kumar R, Gupta A, Lohiya NK, et al:
A novel cancer testis antigen target A-kinase anchor protein
(AKAP4) for the early diagnosis and immunotherapy of colon cancer.
OncoImmunology. 5:e10789652016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang
C, Wang D, Wang C, Wang Z, Wang M, et al: China experts consensus
on the diagnosis and treatment of advanced stage primary lung
cancer (2016 Version). (In Chinese). View Article : Google Scholar
|
|
14
|
Cui Y, Zhang F, Zhu C, Geng L, Tian T and
Liu H: Upregulated lncRNA SNHG1 contributes to progression of
non-small cell lung cancer through inhibition of miR-101-3p and
activation of Wnt/β-catenin signaling pathway. Oncotarget.
8:17785–17794. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Q, Wang Q, Wang SF, Jiao LJ, Zhang
RX, Zhong Y, Zhang J and Xu L: Oral Chinese herbal medicine as
maintenance treatment after chemotherapy for advanced
non-small-cell lung cancer: A systematic review and meta-analysis.
Curr Oncol. 24:269–276. 2017. View Article : Google Scholar
|
|
16
|
Vesel M, Rapp J, Feller D, Kiss E, Jaromi
L, Meggyes M, Miskei G, Duga B, Smuk G, Laszlo T, et al: ABCB1 and
ABCG2 drug transporters are differentially expressed in non-small
cell lung cancers (NSCLC) and expression is modified by cisplatin
treatment via altered Wnt signaling. Respir Res. 18:522017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jia QP, Yan CY, Zheng XR, Pan X, Cao X and
Cao L: Upregulation of MTA1 expression by human papillomavirus
infection promotes CDDP resistance in cervical cancer cells via
modulation of NF-κB/APOBEC3B cascade. Cancer Chemother Pharmacol.
83:625–637. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bui-Nguyen TM, Pakala SB, Sirigiri DR,
Martin E, Murad F and Kumar R: Stimulation of inducible nitric
oxide by hepatitis B virus transactivator protein-HBx requires MTA1
coregulator. J Biol Chem. 292:47652017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li HS, Lv RQ and Liu L: Correlation of CT
indicators of NSCLC and pathological features and the expression
level of p53 and c-myc. Eur Rev Med Pharmacol Sci. 22:135–141.
2018.PubMed/NCBI
|
|
20
|
Lee J, Cui Y, Sun X, Li B, Wu J, Li D,
Gensheimer MF, Loo BW Jr, Diehn M and Li R: Prognostic value and
molecular correlates of a CT image-based quantitative pleural
contact index in early stage NSCLC. Eur Radiol. 28:736–746. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abel S, Hasan S, White R, Schumacher L,
Finley G, Colonias A and Wegner RE: Stereotactic ablative
radiotherapy (SABR) in early stage non-small cell lung cancer:
Comparing survival outcomes in adenocarcinoma and squamous cell
carcinoma. Lung Cancer. 128:127–133. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carrascosa P and Capunay C: Myocardial CT
perfusion imaging for ischemia detection. Cardiovasc Diagn Ther.
7:112–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chu LL, Knebel RJ, Shay AD, Santos J,
Badawi RD, Gandara DR and Knollmann FD: CT perfusion imaging of
lung cancer: Benefit of motion correction for blood flow estimates.
Eur Radiol. 28:5069–5075. 2018. View Article : Google Scholar : PubMed/NCBI
|
